40 years of cancer evolution: time to understand its clinical implications
Tumor heterogeneity is observed at many levels: from cancer subclones in primary tumor with distinct characteristics to differences between primary and… Read more »
Dr Shanthini Crusz is a Clinical Research Fellow at Barts Cancer Institute in London where she studies clinical implications of intratumour heterogeneity and contribution of immune cells to metastatic pancreatic cancer progression.
Dr Marco Gerlinger is a Clinician Scientist in the Centre for Evolution and Cancer at the Institute of Cancer Research, London and a Consultant Medical Oncologist at the Royal Marsden Hospital in London. His work focuses on understanding and controlling cancer evolution in solid tumours through adaptive therapy approaches, drug resistance reversal and combination immunotherapies.
Dr Marco Gerlinger is a Clinician Scientist in the Centre for Evolution and Cancer at the Institute of Cancer Research, London and a Consultant Medical Oncologist at the Royal Marsden Hospital in London. His work focuses on understanding and controlling cancer evolution in solid tumours through adaptive therapy approaches, drug resistance reversal and combination immunotherapies.
Latest posts by Dr Shanthini Crusz & Dr Marco Gerlinger (see all)
- 40 years of cancer evolution: time to understand its clinical implications - 14th November 2016